Literature DB >> 22766432

Abatacept use in rheumatoid arthritis: evidence review and recommendations.

Emilio Martín Mola1, Alejandro Balsa, Víctor Martínez Taboada, Raimon Sanmartí, José Luis Marenco, Federico Navarro Sarabia, Juan Gómez-Reino, José María Alvaro-Gracia, José Andrés Román Ivorra, Leticia Lojo, Chamaida Plasencia, Loreto Carmona.   

Abstract

OBJECTIVE: To review the clinical evidence on abatacept and to formulate recommendations in order to clear up points related to its use in rheumatology.
METHOD: An expert panel of rheumatologists objectively summarized the evidence on the mechanism of action, practicalities, effectiveness and safety of abatacept, and formulated recommendations following a literature review. The level of evidence and degree of recommendation was established.
RESULTS: The document presents 21 statements focused on evidence or recommendations on abatacept (14 evidence summaries and 9 recommendations). The level of evidence was 2b or higher according to the Oxford Centre for Evidence-Based Medicine scale on 14 occasions. The degree of the recommendation was A in two recommendations, C in one, and D in the rest. It was considered important to make recommendations on aspects with lower levels of evidence.
CONCLUSIONS: This is a practical document to supplement the summary of product characteristics.
Copyright © 2012 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22766432     DOI: 10.1016/j.reuma.2012.05.001

Source DB:  PubMed          Journal:  Reumatol Clin        ISSN: 1699-258X


  6 in total

Review 1.  Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.

Authors:  Emilio Martin-Mola; Alejandro Balsa; Rosario García-Vicuna; Juan Gómez-Reino; Miguel Angel González-Gay; Raimon Sanmartí; Estíbaliz Loza
Journal:  Rheumatol Int       Date:  2016-06-06       Impact factor: 2.631

Review 2.  Abatacept: a review of its use in the management of rheumatoid arthritis.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

3.  Gene and protein expression of a soluble form of CTLA-4 in a healthy dog.

Authors:  Michihito Tagawa; Yuhei Yamamoto; Genya Shimbo; Aiko Iguchi; Xuenan Xuan; Mizuki Tomihari; Kazuro Miyahara
Journal:  J Vet Med Sci       Date:  2017-04-07       Impact factor: 1.267

4.  Application of nSMOL coupled with LC-MS bioanalysis for monitoring the Fc-fusion biopharmaceuticals Etanercept and Abatacept in human serum.

Authors:  Noriko Iwamoto; Kotoko Yokoyama; Megumi Takanashi; Atsushi Yonezawa; Kazuo Matsubara; Takashi Shimada
Journal:  Pharmacol Res Perspect       Date:  2018-07-24

Review 5.  Lessons From the Success and Failure of Targeted Drugs for Rheumatoid Arthritis: Perspectives for Effective Basic and Translational Research.

Authors:  Mingyo Kim; Yong-Ho Choe; Sang-Il Lee
Journal:  Immune Netw       Date:  2022-02-22       Impact factor: 5.851

Review 6.  Recommendations on the management of adult patients with rheumatic diseases in the context of SARS-CoV-2/COVID-19 infection. Colombian Association of Rheumatology.

Authors:  Lina María Saldarriaga Rivera; Daniel Fernández Ávila; Wilson Bautista Molano; Daniel Jaramillo Arroyave; Alain Jasaf Bautista Ramírez; Adriana Díaz Maldonado; Jorge Hernán Izquierdo; Edwin Jáuregui; María Constanza Latorre Muñoz; Juan Pablo Restrepo; Juan Sebastián Segura Charry
Journal:  Reumatol Clin (Engl Ed)       Date:  2020-07-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.